Advances in diagnosis and treatment of malignant pleural mesothelioma

被引：2
作者：
Scagliotti, Giorgio Vittorio [1 ,2 ]
Selvaggi, Giovanni [2 ]
机构：
[1] Univ Turin, Dept Clin & Biol Sci, Thorac Oncol Unit, San Luigi Hosp, Reg Gonzole 10, I-10043 Orbassano, TO, Italy
[2] Univ Turin, Dept Clin & Biol Sci, Thorac Oncol UNIT, San Luigi Hosp, Turin, Italy
来源：
ONCOLOGY REVIEWS | 2007年 / 1卷 / 02期
关键词：
Malignant Pleural Mesothelioma; Prognostic Factors; Mesothelin; Osteopontin; Chemotherapy; Pemetrexed; Targeted Therapy; Vascular Endothelial Growth Factor; Epidermal Growth Factor;
D O I：
10.1007/s12156-007-0011-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and presentation of disease. New diagnostic procedures are urgently needed, selecting patients in earlier stages to evaluate therapeutic approaches which combine chemotherapy, surgery and radiotherapy. Combination chemotherapy represents the only resource available for advanced disease. The combination of cisplatin and pemetrexed is the treatment of choice. This review summarizes the latest developments in diagnostic techniques and the available therapeutic options for the management of MPM. Particular attention is given to the molecular basis of biologically targeted therapies to be used in the future.
引用
收藏
页码：91 / 102
页数：12
相关论文
共 106 条
[1]   Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest [J].
Ahamad, A ;
Stevens, CW ;
Smythe, WR ;
Liao, ZX ;
Vaporciyan, AA ;
Rice, D ;
Walsh, G ;
Guerrero, T ;
Chang, J ;
Bell, B ;
Komaki, R ;
Forster, KM .
CANCER JOURNAL, 2003, 9 (06) :476-484
[2]  
Aoe K, 2006, ANTICANCER RES, V26, P4833
[3]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[4]   The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma:: an EORTC phase II study (08992) [J].
Baas, P ;
Ardizzoni, A ;
Grossi, F ;
Nackaerts, K ;
Numico, G ;
Van Marck, E ;
van de Vijver, M ;
Monetti, F ;
Smid-Geirnaerdt, MJA ;
van Zandwijk, N ;
Debruyne, C ;
Legrand, C ;
Giaccone, G .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (03) :353-357
[5]   Thalidomide in patients with malignant pleural mesothelioma [J].
Baas, P ;
Boogerd, W ;
Dalesio, O ;
Haringhuizen, A ;
Custers, F ;
van Zandwijk, N .
LUNG CANCER, 2005, 48 (02) :291-296
[6]   THE TREATMENT OF MALIGNANT MESOTHELIOMA OF THE PLEURA - REVIEW OF A 5-YEAR EXPERIENCE, WITH SPECIAL REFERENCE TO RADIOTHERAPY [J].
BALL, DL ;
CRUICKSHANK, DG .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (01) :4-9
[7]   RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer [J].
Bepler, Gerold ;
Kusmartseva, Irina ;
Sharma, Swati ;
Gautam, Ashish ;
Cantor, Alan ;
Sharma, Anupama ;
Simon, George .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4731-4737
[8]   Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis [J].
Berghmans, T ;
Paesmans, M ;
Lalami, Y ;
Louviaux, I ;
Luce, S ;
Mascaux, C ;
Meert, AP ;
Sculier, JP .
LUNG CANCER, 2002, 38 (02) :111-121
[9]   MESOMARK™:: A potential test for malignant pleural mesothelioma [J].
Beyer, Heather L. ;
Geschwindt, Ryan D. ;
Glover, Curtis L. ;
Tran, Ly ;
Hellstrom, Ingegerd ;
Hellstrom, Karl-Erik ;
Miller, M. Craig ;
Verch, Thorsten ;
Allard, W. Jeffrey ;
Pass, Harvey I. ;
Sardesai, Niranjan Y. .
CLINICAL CHEMISTRY, 2007, 53 (04) :666-672
[10]   PREVENTION OF MALIGNANT SEEDING AFTER INVASIVE DIAGNOSTIC PROCEDURES IN PATIENTS WITH PLEURAL MESOTHELIOMA - A RANDOMIZED TRIAL OF LOCAL RADIOTHERAPY [J].
BOUTIN, C ;
REY, F ;
VIALLAT, JR .
CHEST, 1995, 108 (03) :754-758
12345678910